Literature DB >> 21287809

Novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2 and Bax in osteosarcoma cells.

Guowen Wang1, Jiesheng Rong, Zhihong Zhou, Jian Duo.   

Abstract

As previously reported, a novel gene P28GANK conferred a multidrug resistant phenotype in gastric cancer cells. The aim of this study was to explore the role of P28GANK in the development of multidrug resistance (MDR) in osteosarcoma cells. P28GANK gene was found to be overexpressed at the mRNA level and the protein level in a cisplatin induced MDR osteosarcoma cell line Saos-2/CDDP compared to its parent cell line Saos-2. Here, we transfected the osteosarcoma cell line Saos-2 with eukaryotic expression vector of P28GANK. In vitro drug sensitivity assay suggested that Saos-2-P28GANK cells conferred resistance to both P-glycoprotein (P-gp)-related and P-gp-nonrelated drugs. Blocking P28GANK expression in MDR osteosarcoma cells Saos-2/CDDP by P28GANK-specific small interfering RNA (siRNA) increased the cell sensitivity to various chemotherapeutic drugs. Flow cytometry examination suggested that P28GANK gene expression could suppress Adriamycin-induced apoptosis accompanied by decreased accumulation and increased release of Adriamycin. Semiquantitative RT-PCR, Western blot and Luciferase reporter assay suggested that P28GANK gene could significantly up-regulate the expression of MDR-1 and Bcl-2, transcription of the MDR-1 gene and down-regulate the expression of Bax. In addition, inhibition of P28GANK expression by RNA interference or P-gp inhibition could partially reverse P28GANK-mediated MDR. Taken together, our findings suggest that down-regulation of P28GANK gene expression could sensitize osteosarcoma cells to chemotherapeutic drugs by down-regulation of the MDR-1 and Bcl-2 and up-regulation of Bax gene expression, without altering the glutathione S-transferase activity, or intracellular glutathione content in osteosarcoma cells. Further study on biological function of P28GANK may be helpful for understanding MDR mechanism of osteosarcoma and developing a strategy for osteosarcoma treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21287809

Source DB:  PubMed          Journal:  Mol Biol (Mosk)        ISSN: 0026-8984


  10 in total

1.  TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances.

Authors:  Xiu-Guo Han; Yan Li; Hui-Min Mo; Kang Li; Du Lin; Chang-Qing Zhao; Jie Zhao; Ting-Ting Tang
Journal:  Tumour Biol       Date:  2016-01-09

2.  Regulatory mechanism of ZNF139 in multi-drug resistance of gastric cancer cells.

Authors:  Yong Li; Bi-bo Tan; Qun Zhao; Li-qiao Fan; Yü Liu; Dong Wang
Journal:  Mol Biol Rep       Date:  2014-02-11       Impact factor: 2.316

Review 3.  Gankyrin regulates cell signaling network.

Authors:  Xinxin Wang; Bin Jiang; Yanjie Zhang
Journal:  Tumour Biol       Date:  2016-01-27

4.  PERK-mediated Autophagy in Osteosarcoma Cells Resists ER Stress-induced Cell Apoptosis.

Authors:  Guang-rong Ji; Nai-chun Yu; Xiang Xue; Zong-guang Li
Journal:  Int J Biol Sci       Date:  2015-05-23       Impact factor: 6.580

5.  Unexpected Lower Expression of Oncoprotein Gankyrin in Drug Resistant ABCG2 Overexpressing Breast Cancer Cell Lines

Authors:  Taheri Taheri; Khadijeh Jamialahmadi; Fatemeh Khadijeh
Journal:  Asian Pac J Cancer Prev       Date:  2017-12-29

6.  [Establishment of animal model of a human lung adenocarcinoma drug-resistant
cell line Anip973/NVB and investigation on mechanism of drug resistance].

Authors:  Meng Wang; Xuan Hong; Qinwen Sun; Ruilin Li; Zhaoyang Yang; Gongyan Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-03

Review 7.  Chemoresistance-Related Stem Cell Signaling in Osteosarcoma and Its Plausible Contribution to Poor Therapeutic Response: A Discussion That Still Matters.

Authors:  Sara R Martins-Neves; Gabriela Sampaio-Ribeiro; Célia M F Gomes
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

8.  MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma.

Authors:  Guangyi Zhao; Chengkui Cai; Tongtao Yang; Xiuchun Qiu; Bo Liao; Wei Li; Zhenwei Ji; Jian Zhao; Haien Zhao; Mingjun Guo; Qiong Ma; Chun Xiao; Qingyu Fan; Baoan Ma
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

9.  miR-133b induces chemoresistance of osteosarcoma cells to cisplatin treatment by promoting cell death, migration and invasion.

Authors:  Yonggen Zou; Jiexiang Yang; Jian Wu; Cheng Luo; Yuanshuai Huang
Journal:  Oncol Lett       Date:  2017-11-16       Impact factor: 2.967

10.  TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma.

Authors:  Cuiyun Li; Jing Cai; Fugui Ge; Guilong Wang
Journal:  Int J Mol Med       Date:  2018-07-04       Impact factor: 4.101

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.